LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights. “Silence’s first quarter performance reflects another period of solid execution with the continued advancement of both our wholly owned and partnered pipelines in the clinic,” said Craig Tooman, President and Chief Executive Off...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About Silence Th...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence’s Chairman of the Board, commented, “Alistair has made significant contributions to the Board and the Company over ...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA), Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key gen...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights. “2023 was a year of strong execution across Silence as we advanced our proprietary pipeline in the clinic,” said Craig Tooman, President and CEO of Silence. “That’s clearly bearing fruit today with the positive topline 36-week d...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s producti...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024. Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update. The conferen...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence. “This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the cl...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced an oversubscribed private placement of 5,714,286 of the Company’s American Depositary Shares (“ADSs”)1 at a purchase price of US $21.00 per ADS, representing a premium of approximately 11% to Silence’s 30-day volume-weighted average price, with both new and existing institutional and accredited investors (the “Private Placement”). S...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7th at 1:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About S...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie Wikström Lindholm, PhD, previously Silence’s Senior Vice President, Head of Molecular Design, has been promoted to Chief Scientific Officer, effective immediately. This press release features mult...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights. “This has been a year of strong execution across Silence,” said Craig Tooman, President and CEO at Silence. “We continue to see great results emerge from our mRNAi GOLD™ platform, including the very rapid enrollment of our z...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, Silence President and CEO, will present a corporate update at the Jefferies London Healthcare Conference on Wednesday, November 15th at 4:30 p.m. GMT. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline results from the multiple dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L and stable atherosclerotic cardiovascular disease (ASCVD). Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s p...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines Conference on Tuesday, October 3rd at 8:00 a.m. ET. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About Silence Therapeuti...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Company management will participate in the following investor conferences and invited investors to participate by webcast. Morgan Stanley Global Healthcare Conference Fireside Chat on Monday, September 11, 2023 at 9:20am EDT HC Wainwright Global Investment Conference Fireside Chat on Tuesday, September 12, 2023 at 10am EDT...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights. “Silence’s strong second quarter results reflect continued execution and meaningful pipeline progress,” said Craig Tooman, President and Chief Executive Officer at Silence. “We look forward to multiple clinical data readouts in ...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precision engineered medicines, today announced that it will receive a $4.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of two undisclosed preclinical milestones. “We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silence. “Today’s ...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:00 – 4:25 PM EDT. A live webcast of the presentation can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available on the Company’s website following the conference. About Si...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights. “2023 has been marked by strong execution across all areas of our business,” said Craig Tooman, President and Chief Executive Officer at Silence. “We completed enrollment in the zerlasiran phase 2 study in four months which exce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.